Authors


Yiming Wu, PhD

Latest:

Dr Wu on the Role of METTL3-Mediated m6A Modification in CLL Progression

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.


Vadim S. Koshkin, MD

Latest:

Treating R/R Advanced Bladder Cancer With Novel Sequencing Strategies

UCSF Health’s Vadim S. Koshkin, MD, highlights approaches for sequencing novel therapies into treatment algorithms for patients with relapsed/refractory advanced bladder cancer.


Edward Kim, MD, Mount Sinai Medical Center

Latest:

Dr. Kim on the Future Role of Y-90 in Patients with Unresectable HCC

Edward Kim, MD, discusses the future role of Y-90 in patients with unresectable hepatocellular carcinoma.



Avyakta Kallam, MBBS

Latest:

Dr. Kallam on the Role of BTK and PI3K Inhibitors in CNS Lymphoma

Avyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.


Jacob J. Adashek, DO

Latest:

Dr. Adashek on Targeting Molecular Alterations to Treat Multiple Tumor Types

Jacob J. Adashek, DO, discusses how targeting molecular alterations is key for treating multiple types of cancer.


Sepideh Gholami, MD, FACS, UC Davis Comprehensive Cancer Center

Latest:

ASCO GI 2021: MRD Detection With ctDNA From Assays

Expert physicians discuss data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) 2021 annual meeting, regarding minimal residual disease (MRD) detection with ctDNA (circulating tumor DNA) from personalized assays in stage II and III patients with colorectal cancer. 


Johannes Zakrzewski, MD

Latest:

Dr. Zakrzewski on Investigation of IT848 Nanotherapy in Hematologic Malignancies

Johannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.


Alicia Morgans, MD, MPH

Latest:

Prostate Cancer Management: Future Directions in Care

Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.


Richard J. Bleicher, MD, FACS

Latest:

Fellows on Film: How To Market Yourself for a Fellowship

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss how to market oneself for a fellowship in oncology.


Stephen Liu, MD

Latest:

Dr Liu on the Benefits of Biomarker Testing in NSCLC

Stephen V. Liu, MD, discusses the benefits of conducting biomarker testing for patients with advanced non–small cell lung cancer and highlights the importance of waiting for the results before selecting a targeted treatment.


Lipika Goyal, MD

Latest:

Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma

Provider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.


Matthew Lunning, DO, FACP

Latest:

Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies

Dr Lunning sits down with Alex Herrera, MD, to discuss the frontline management of Hodgkin lymphoma, including the SWOG 1826 trial.


Alex Duval, MD, PhD

Latest:

Dr. Duval on the Use of MSI-H as a Biomarker of Response in Patients With Cancer

Alex Duval, MD, PhD, discusses the use of microsatellite instability–high as a biomarker of response to therapy in patients with cancer.


Cortney Eakin, MD

Latest:

Dr. Eakin on Racial Disparities in Uterine Cancer

Cortney Eakin, MD, discusses racial disparities and histology trends in uterine cancer.


Sasha Stanton, MD

Latest:

Dr. Stanton on Improving Responses to Immunotherapy in Early-Stage HR+ Breast Cancer

Sasha Stanton, MD, discusses efforts to improve the responses to immunotherapy regimens in early-stage hormone receptor–positive breast cancer.


Morgan Bayer

Latest:

Cilta-Cel Sustains MRD-Negative Responses in Previously Treated Multiple Myeloma

Cilta-cel continues to elicit deep and durable responses in patients with early relapsed multiple myeloma, including those refractory to lenalidomide.


Christopher Morse, MD

Latest:

Taking Action to Individualize Ovarian Cancer Care: Key Takeaways

In this fifth episode of OncChats: Taking Action to Individualize Ovarian Cancer Care, John Nakayama, MD, and Christopher Morse, MD, share key takeaways from their discussion on how to best individualize care for patients with ovarian cancer.


April Rose, MD

Latest:

Dr. Rose on the Results of the BEAVER Trial in Non-V600E BRAF-Mutant Advanced Solid Tumors

April Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.


Joshua Strauss, MD

Latest:

Dr. Strauss on Future Research Directions in SCLC

Joshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.


Sanjeet Singh Dadwal, MD

Latest:

Dr. Dadwal on the Investigation of Posoleucel Following Allogeneic HCT

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.


Lindsay Fischer

Latest:

Fostering Interactions That Heal

The pain and suffering that Eduardo Bruera, MD, FAAHPM, witnessed in patients during his clinical oncology rotations motivated him to reshape palliative care treatment.


Bradley Monk, MD, FACS, FACOG

Latest:

Dr Monk on the Investigation of B7-H4–Directed Vedotin ADCs in Gynecologic Cancers

Bradley Monk, MD, FACS, FACOG, discusses the rationale for investigating B7-H4–directed vedotin antibody-drug conjugates and highlights how these agents may address unmet needs for patients with gynecologic cancers.


Guillermo Garcia-Manero, MD

Latest:

Managing AEs Associated with HMA Treatment

Guillermo Garcia-Manero, MD, reviews potential serious and common adverse effects associated with HMA treatments, shares tips for patient education to help manage these AEs, and discusses if and when a dose reduction or discontinuation may be necessary.


Alexander Putnam Cole, MD

Latest:

Dr Cole on the Rationale for Investigating Race-based Disparities in Prostate Cancer–Specific Survival

Alexander Putnam Cole, MD, discusses the rationale for investigating the magnitude of racial and ethnic disparities in prostate cancer–specific survival in patients undergoing surgery vs radiotherapy.


James Catto, MB, ChB, PhD, FRCS

Latest:

Dr Catto on the Utility of Erdafitinib in High-Risk nMIBC With FGFR Alterations

James Catto, MB, ChB, PhD, FRCS, discusses the utility of erdafitinib in patients with high-risk non–muscle-invasive bladder cancer with select FGFR alterations who have received prior treatment with Bacillus Calmette–Guérin.


Zaraq Khan, MBBS

Latest:

Dr. Khan on the Ideal Patients for GnRH Agonists in Breast Cancer

Zaraq Khan, MBBS, discusses which patients with breast cancer would be ideal candidates to receive treatment with a GnRH agonist for ovarian protection.


Nicolaus Kröger, MD

Latest:

Dr. Kröger on Toxicities Associated With Allogeneic Stem Cell Transplant in Myeloma

Nicolaus Kröger, MD, discusses toxicities associated with allogeneic stem cell transplant in patients with multiple myeloma.


Neil M. Iyengar, MD

Latest:

Dr. Iyengar on the Benefit of Trastuzumab Deruxtecan in Metastatic HER2+ Breast Cancer After T-DM1

Neil M. Iyengar, MD, discusses the expanding investigation and role of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.


Benjamin Garmezy, MD

Latest:

Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC

David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.